LIVZON PHARMAC. GRP H YC1 (LP6) — Tangible Net Worth Ratio
LIVZON PHARMAC. GRP H YC1 (LP6) has a Tangible Net Worth Ratio of 94.7% as of March 2026. This metric is calculated by deducting intangible assets (€830.34 Million) from net assets (€15.58 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore LIVZON PHARMAC. GRP H YC1 annual equity growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
LIVZON PHARMAC. GRP H YC1 Tangible Net Worth Ratio (2021–2025)
This chart shows how LIVZON PHARMAC. GRP H YC1's Tangible Net Worth Ratio has changed across 5 annual periods from 2021 to 2025. As of March 2026, the ratio stands at 94.7%, reflecting net assets of €15.58 Billion with intangible assets of €830.34 Million EUR. For live market cap and overall valuation, see LP6 market cap.
Annual Tangible Net Worth Ratio for LIVZON PHARMAC. GRP H YC1 (2021–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for LIVZON PHARMAC. GRP H YC1 from 2021 to 2025, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore LP6 capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.6% | €15.55 Billion | €833.72 Million | €23.99 Billion | ▼ -1.2 pp |
| 2024 | 95.8% | €14.91 Billion | €624.18 Million | €24.46 Billion | ▲ +0.6 pp |
| 2023 | 95.2% | €14.77 Billion | €714.17 Million | €25.04 Billion | ▲ +0.7 pp |
| 2022 | 94.5% | €14.94 Billion | €826.39 Million | €24.87 Billion | ▲ +0.3 pp |
| 2021 | 94.2% | €14.31 Billion | €834.78 Million | €22.37 Billion | — |